Table 1.
Characteristics of the studied population
| Patient no. | Sex (M/F) | Age (years) | Underlying nephropathy | Comorbidities | Medication | Dry weight (kg) | Dialyzer surface | Kt/V | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| area (m2) | ||||||||||||
| Ischaemic | Diabetes | Beta | Calcium | Alpha | ACE-inhibitors | |||||||
| cardiomyopathy | mellitus | blockers | antagonists | blockers | or ARB | |||||||
| 1 | F | 74 | Diabetic nephropathy | Y | Y | Y | N | N | Y | 70.0 | 1.8 | 1.59 |
| 2 | F | 87 | Nephroangiosclerosis | N | N | Y | Y | N | Y | 63.0 | 1.8 | 1.38 |
| 3 | M | 71 | Diabetic nephropathy | Y | Y | N | N | N | Y | 85.0 | 1.8 | 1.28 |
| 4 | F | 84 | Rapidly progressive glomerulonephritis | Y | N | Y | Y | Y | Y | 57.5 | 1.8 | 1.88 |
| 5 | M | 79 | Diabetic nephropathy | Y | Y | N | N | N | N | 62.0 | 1.8 | 1.28 |
| 6 | F | 56 | Focal segmental glomerulosclerosis | N | N | Y | Y | N | N | 104.0 | 1.8 | 1.81 |
| 7 | M | 58 | Focal segmental glomerulosclerosis | N | Y | Y | Y | N | N | 80.0 | 2.2 | 1.46 |
| 8 | F | 79 | Rapidly progressive glomerulonephritis | Y | N | Y | N | N | N | 44.0 | 1.8 | 1.85 |
| 9 | M | 64 | Focal segmental glomerulosclerosis | N | N | Y | N | N | N | 81.0 | 1.8 | 1.49 |
| 10 | F | 73 | Diabetic nephropathy | N | Y | N | Y | N | N | 83.0 | 1.8 | 1.32 |
| 11 | M | 63 | Nephroangiosclerosis | Y | N | Y | N | N | Y | 95.0 | 2.2 | 1.28 |
| 12 | M | 73 | Nephroangiosclerosis | N | N | N | N | N | N | 72.5 | 1.8 | 1.64 |
| 13 | F | 63 | Focal segmental glomerulosclerosis | N | N | N | N | N | N | 42.5 | 1.4 | 1.69 |
| 14 | M | 71 | Diabetic nephropathy | Y | Y | N | N | N | Y | 79.0 | 1.8 | 1.29 |
| 15 | M | 82 | Relapsing nephrolithiasis | N | Y | N | N | N | N | 63.0 | 1.8 | 1.61 |
| 16 | F | 47 | IgA nephropathy | N | Y | N | N | N | N | 71.5 | 2.2 | 2.0 |
| 17 | M | 72 | Nephroangiosclerosis and bilateral a.renalis stenosis | Y | N | Y | Y | N | Y | 68.25 | 2.2 | 1.32 |
| 18 | F | 63 | Relapsing pyelonephritis | N | N | Y | Y | N | N | 57.0 | 1.8 | 1.84 |
| 19 | M | 67 | Nephroangiosclerosis | N | N | N | N | N | Y | 72.0 | 2.2 | 1.6 |
| 20 | F | 62 | Nephroangiosclerosis | N | N | Y | N | N | Y | 64.0 | 1.8 | 1.65 |
| 21 | F | 64 | Diabetic nephropathy | Y | Y | Y | Y | Y | Y | 51.0 | 1.8 | 2.18 |
Characteristics of the cohort at the beginning of the study.
M: male; F: female; Y: yes; N: no; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor antagonists.